Core Viewpoint - Hanghua Co., Ltd. announced plans to allocate approximately 145.75 million yuan from surplus funds and cash management income to establish a new project for producing 35,000 tons of green printing new materials after completing previous projects [1] Group 1 - The company intends to use the remaining funds from the "annual production of 10,000 tons of liquid ink and 8,000 tons of functional materials project (Phase II)" and the "new materials research and development center project" [1] - The total amount allocated for the new project is approximately 145.75 million yuan, which includes surplus funds, cash management income, and interest income [1] - The project will be submitted for approval at the shareholders' meeting, with no objections from the sponsor, Zheshang Securities [1]

Core Viewpoint - The company has announced adjustments to its fundraising projects, reallocating funds to a new project aimed at producing 35,000 tons of green printing materials, which will enhance its competitive edge in the market [1][2][3] Group 1: Project Details - The company will invest in a new project with a total estimated investment of 1 billion yuan, which includes various costs such as construction, equipment, and working capital [1] - The new project will utilize a digital intelligent manufacturing approach to produce 15,000 tons of UV curing printing materials and 20,000 tons of plant oil-based printing materials [1][2] - The company plans to use approximately 146 million yuan from surplus fundraising and project completion funds for this new project [1] Group 2: Strategic Importance - The new project aligns with the regional development strategy of the Hangzhou Qiantang New District, focusing on new materials as a strategic driver [2] - The company aims to enhance production efficiency and product quality through technological upgrades and digital management, ensuring a competitive advantage in the high-end printing ink market [2][3] - The adjustments in fundraising and project focus are seen as a prudent decision to optimize resource allocation and improve economic benefits, supporting the company's long-term growth [3]

证券日报网讯 12月23日晚间，杭华股份发布公告称，董事会于近日收到公司非独立董事曹文旭先生提 交的书面辞任报告。因公司控制权变更而涉及董事会改组调整，曹文旭先生申请辞去公司第四届董事会 非独立董事职务同时辞去第四届董事会战略委员会委员职务。辞任后，曹文旭先生将继续在公司担任副 总经理职务。公司于2025年12月23日召开第四届董事会第十七次会议，审议通过《关于补选公司第四届 董事会非独立董事并调整董事会战略委员会委员的议案》，同意推选肖梦媛女士为公司第四届董事会非 独立董事候选人，任期自股东会审议通过之日起至公司第四届董事会任期届满之日止。 （文章来源：证券日报） ...

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

证券代码：688571 证券简称：杭华股份 公告编号：2025-065 杭华油墨股份有限公司 关于董事辞任暨补选公司第四届董事会非独立董事 并调整董事会战略委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●杭华油墨股份有限公司（以下简称"公司"或"杭华股份）"董事会于近 日收到公司非独立董事曹文旭先生提交的书面辞任报告。因公司控制权变更而涉 及董事会改组调整，曹文旭先生申请辞去公司第四届董事会非独立董事职务同时 辞去第四届董事会战略委员会委员职务。辞任后，曹文旭先生将继续在公司担任 副总经理职务。 ●公司于 2025 年 12 月 23 日召开第四届董事会第十七次会议，审议通过《关 于补选公司第四届董事会非独立董事并调整董事会战略委员会委员的议案》，同 意推选肖梦媛女士为公司第四届董事会非独立董事候选人，任期自股东会审议通 过之日起至公司第四届董事会任期届满之日止，该事项尚需提交公司股东会审议。 同时在公司股东会审议通过选举肖梦媛女士为公司第四届董事会非独立董事之 日起，选举肖梦媛女士为公 ...

●现金管理额度：在保证不影响公司募集资金投资计划正常进行的前提下， 杭华油墨股份有限公司（以下简称"公司"或"杭华股份"）及募投项目实施子 公司使用最高额度不超过人民币 10,000 万元（含本数）的暂时闲置募集资金进 行现金管理，使用期限不超过 12 个月。在前述额度及期限范围内，公司及募投 项目实施子公司可以循环滚动使用。 ●已履行及拟履行的审议程序：公司分别于 2025 年 12 月 11 日、2025 年 12 月 23 日召开公司第四届董事会审计委员会第十四次会议和第四届董事会第十七 次会议，审议并通过《关于使用部分暂时闲置募集资金进行现金管理的议案》， 本事项无需提交公司股东会审议。公司保荐机构浙商证券股份有限公司对上述事 项出具了明确同意的核查意见。 证券代码：688571 证券简称：杭华股份 公告编号：2025-063 杭华油墨股份有限公司 关于使用部分暂时闲置募集资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●投资种类：安全性高、流动性好的、满足保本要求的投资产 ...

证券代码：688571 证券简称：杭华股份 公告编号：2025-061 杭华油墨股份有限公司 关于部分募投项目调整建设投资规模、结项并将节余 募集资金用于新增募投项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭华油墨股份有限公司（以下简称"公司"或"杭华股份"）于 2025 年 12 月 23 日召开的第四届董事会第十七次会议，审议通过了《关于部分募投项目调 整建设投资规模、结项并将节余募集资金用于新增募投项目的议案》，同意公司 调整首次公开发行募集资金投资项目"年产 1 万吨液体油墨及 8,000 吨功能材料 项目（二期工程）""新材料研发中心项目"建设投资规模并结项，同时将节余 募集资金及结项募投项目资金在募集资金专用账户存储期间产生的各项现金管 理收益、利息收入等共计约人民币 14,574.56 万元（最终以募集资金专用账户实 际转出金额为准）全部用于在杭州市钱塘区临江高科园实施新建"年产 35,000 吨绿色印刷新材料项目"。保荐机构浙商证券股份有限公司对本事项出具了无异 议的核查意见，本事项将提交公 ...

证券代码：688571 证券简称：杭华股份 公告编号：2025-062 杭华油墨股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ●是否需要提交股东会审议：是 ●日常关联交易对上市公司的影响：本次预计的关联交易属公司及子公司日 常关联交易，以正常生产经营业务为基础，以市场价格为定价依据，不影响公司 的独立性，不存在损害公司及股东利益的情形，不会对关联人形成较大的依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 杭华油墨股份有限公司（以下简称"公司"或"杭华股份"）于 2025 年 12 月 23 日召开了公司第四届董事会第十七次会议，审议并通过《关于 2026 年度日 常关联交易预计的议案》，本次日常关联交易预计金额合计为人民币 8,751.00 万元。关联董事中間和彦先生回避表决，出席会议的非关联董事一致同意该项议 案。 注 1：2025 年 1 月至 4 月浙江迪克东华精细化工有限公司（以下简称"浙江迪克"）为株式会社 T&K TOKA （以下简 ...

证券代码：688571 证券简称：杭华股份 公告编号：2025-064 杭华油墨股份有限公司 关于使用部分自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 30,000 万元 | | --- | --- | | 投资种类 | 安全性高、流动性好、投资回报相对较好的具有合法经营资 | | | 格的金融机构销售的投资产品（包括但不限于结构性存款、 | | | 短期低风险类、固定收益类等理财产品），且该等现金管理 | | | 产品不得用于质押，不用于以证券投资为目的的投资行为。 | | 资金来源 | 自有资金 | 一、投资情况概述 已履行及拟履行的审议程序 杭华油墨股份有限公司（以下简称"公司"或"杭华股份"）分别于 2025 年 12 月 11 日、2025 年 12 月 23 日召开公司第四届董事会审计委员会第十四次 会议和第四届董事会第十七次会议，审议并通过《关于使用部分自有资金进行现 金管理的议案》，本事项无需提交公司股东会审议。 特别风险提示 虽然选 ...

证券代码：688571 证券简称：杭华股份 公告编号：2025-066 杭华油墨股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 1 月 8 日 13 点 30 分 召开地点：浙江省杭州经济技术开发区白杨街道 5 号大街（南）2 号杭华油 墨股份有限公司董事会会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 8 日 至2026 年 1 月 8 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 1 股东会召开日期：2026年1月8日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票 ...